Drug Search Results
More Filters [+]

Zaurategrast

Alternative Names: zaurategrast, cdp-323, cdp323, cdp 323, ct7758
Latest Update: 2011-09-12
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: VCAM-1 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: UCB
Company Location: SMYRNA GA 30080
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zaurategrast

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Multiple Sclerosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2006-002204-33

P2

Completed

Multiple Sclerosis

2010-02-14

C32322

P2

Terminated

Multiple Sclerosis

2009-11-01

C32325

P2

Completed

Multiple Sclerosis

2009-03-01

Recent News Events

Date

Type

Title